

29 June 2020

Our Ref: RFI 34603

Dear

**Freedom of Information Act 2000
Information in Relation to Colorectal Cancer Agents**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 19 May 2020. You will be aware from my previous email that due to the Covid- 19 Pandemic the Information Governance Service was suspended as staff were redeployed. Thank you for your patience and forbearance during the ensuing delay

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Joyce Batch
Information Governance Assistant

Q1. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

A1. The numbers of patients treated in Trust within the past 6 months with the agents you have specified for colorectal cancer are detailed in Table 1 below:

Table 1

CRC Agent	Number of Patients Treated
Aflibercept	0
Bevacizumab	0
Capecitabine	35
CAPIRI	21
CAPOX	24
Cetuximab not in combination with FOLFIRI or FOLFOX	5
Cetuximab in combination with FOLFIRI	11
Cetuximab in combination with FOLFOX	12
Irinotecan	0
FOLFIRI	10
FOLFOX	29
Oxaliplatin	0
Panitumumab not in combination with FOLFIRI or FOLFOX	0
Panitumumab in combination with FOLFIRI	0
Panitumumab in combination with FOLFOX	0
Nivolumab	0
Raltitrexed	0
Ramucirumab	0
Regorafenib	0
Sorafenib	0
5FU only	0
Tegafur Uracil + 5FU	0
Trifluridine–tipiracil	2
XELOX	Same as CAPOX
Other	